US Corporate Distress Financial Stress SEC Filings — October 09, 2026

USA Corporate Distress & Bankruptcy

By Gunpowder Editorial ·

5 high priority 5 total filings analysed

Executive Summary

All five filings in this stream are distress-related, centered on US exchange listing deficiencies rather than bankruptcy filings or going-concern opinions.

The common thread is Nasdaq and NYSE/NYSE American continued-listing enforcement: three companies face sub-$1 bid-price or equity-related deficiencies (Streamex, Accendra Health), and three face governance or filing-compliance failures (Better Home & Finance, IT Tech Packaging), with Alaunos already at the delisting-hearing stage. Because the enriched period-over-period, insider, capital-allocation and forward-looking fields were not populated in these filings, quantitative trend comparisons are not available; the analysis therefore rests on the explicit deadlines, notice dates and materiality ratings disclosed. The most critical development is Alaunos Therapeutics (materiality 8/10), where the October 5, 2026 delisting notice for sub-$2.5M stockholders' equity is now proceeding to a Hearings Panel with a strategic-alternatives process that carries no assured outcome. IT Tech Packaging (8/10) and Better Home & Finance (7/10) also carry near-term enforcement risk, while Streamex and Accendra have the longest cure windows (to April 2027 and roughly April 2027 respectively). Portfolio-level, the pattern is distress manifesting as exchange compliance pressure well ahead of any insolvency event.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 8-K

Tracking the trend? Catch up on the prior US Corporate Distress Financial Stress SEC Filings digest from October 01, 2026.

Investment Signals (7)

  • Delisting notice received October 5, 2026 for failing $2.5M stockholders' equity minimum after April 9, 2026 initial deficiency; Hearings Panel request stays suspension, and a financial advisor is pursuing transactions with no assurance

  • Missed FY2025 10-K and Q1/Q2 2026 10-Q filings; NYSE American accepted extension with plan period to April 15, 2027 and a .LF late-filer flag now attached to the stock

  • Board independence, audit, compensation and nominations rules all breached after October 2 and October 6 board changes; 45-day compliance plan due around late November 2026

  • ▲

    30 consecutive sub-$1.00 closing bids (Aug 25 to Oct 6, 2026); 180-day cure window to April 5, 2027, with possible reverse split as a cure route

  • Accendra Health (formerly Owens & Minor) (BEARISH)
    ▲

    NYSE sub-$1.00 30-day average price notice October 6, 2026; six-month cure period and cure intent notice due within 10 business days

  • Accendra Health (NEUTRAL)
    ▲

    Entity renamed from Owens & Minor per EDGAR header, so ticker and filing history continuity should be checked when tracking the distress trajectory

  • Company submitted a timely compliance plan after the April notice and reports it is working toward transactions it believes would restore all continued-listing criteria, a signal of active management response

Risk Flags (7)

  • Stockholders' equity below $2.5M minimum with delisting notice October 5, 2026; Panel outcome and strategic transaction both uncertain

  • Three periodic reports overdue (FY2025 10-K, Q1 and Q2 2026 10-Qs); delisting proceedings triggered if progress lags or filings incomplete by April 15, 2027

  • Simultaneous failure of majority-independent board, audit committee, compensation committee and independent nominations rules after board resignations and removals; company is an emerging growth company with compliance-plan acceptance not assured

  • 30 consecutive business days below $1.00; if no cure by April 5, 2027, a second 180-day period requires meeting public float value and other initial listing standards and may force a reverse split

  • Accendra Health/Sub-$1 Share Price [MEDIUM RISK]
    ▼

    NYSE average closing price below $1.00 over 30 trading days; repeated sub-$1 pricing can compound financing and index-eligibility pressure

  • Late filings across two fiscal periods suggest possible accounting or internal-control weakness that could widen the scope of the required restatement or review

  • Cross-Filing/Multiple Exchange Deficiencies [MEDIUM RISK]
    ▼

    Stream shows concurrent deficiency notices across NASDAQ and NYSE/NYSE American, indicating broad-based stress rather than isolated listing technicalities

Opportunities (6)

  • Active financial-advisor process for transactions the company says would restore compliance; a deal at a premium could be an event-driven catalyst for distressed-equity investors

  • Reverse split option available before April 5, 2027 deadline, which historically can stabilize share price and restore index eligibility for a sub-$1 name

  • Accendra Health/Cure Path (OPPORTUNITY)
    ◆

    Six-month NYSE cure period with stated intent to pursue compliance; a successful price recovery from sub-$1 would be a rerating catalyst from a depressed base

  • Clearing the delinquent 10-K and 10-Qs and removing the .LF flag would be a discrete re-rating event before the April 15, 2027 deadline

  • Compliance plan due within 45 days could restore board independence and remove the delisting overhang, a potential re-rating if the company is accepted

  • Distressed Event-Driven Screen (OPPORTUNITY)
    ◆

    Four of five names have hard, dated cure deadlines in late 2026 to April 2027, creating a defined catalyst calendar for event-driven distressed strategies

Sector Themes (5)

  • Exchange Listing Deficiency Wave (BEARISH)
    ◆

    All five filings are exchange-driven distress notices (bid price, equity, governance, late filing) rather than bankruptcy or going-concern events, showing distress is currently surfacing through listing enforcement

  • Sub-$1 Bid-Price Pressure (BEARISH)
    ◆

    Two of five filings (Streamex, Accendra) cite 30-day sub-$1.00 pricing under Nasdaq 5550(a)(2) and NYSE 802.01C, with 180-day to six-month cure periods implying reverse-split and restructuring decisions in early 2027

  • Governance and Controls Failures (BEARISH)
    ◆

    Better Home & Finance (board independence) and IT Tech Packaging (late 10-K/10-Q filings) show governance and reporting breakdowns that often precede further enforcement or restatement

  • Cure-Window Calendar Clustering (NEUTRAL)
    ◆

    Deadlines cluster between October 2026 and April 15, 2027 (Better Home compliance plan around late November 2026; Streamex April 5, 2027; IT Tech April 15, 2027), so enforcement outcomes will surface together in the first half of 2027

  • Limited Quantitative Visibility (NEUTRAL)
    ◆

    Period-over-period, insider and capital-allocation enrichments were absent across these filings, so the sector read depends on disclosed deadlines rather than reported financial deterioration; investors should pull the underlying 10-Q/10-K financials to size balance-sheet stress

Watch List (6)

  • Hearing request is due timely after October 5, 2026 notice; watch for Panel decision and any strategic transaction announcement

  • Monitor for delinquent 10-K and 10-Q filings ahead of the April 15, 2027 plan deadline and any appeal of a delisting determination

  • Compliance plan due within 45 calendar days of the October 8, 2026 Nasdaq notice (around November 22, 2026); watch for Nasdaq acceptance and any new board appointments

  • Track daily closing bid against $1.00 and any reverse-split announcement ahead of the April 5, 2027 compliance deadline

  • Accendra Health/NYSE Cure Intent
    👁

    Cure-intent notice due within 10 business days of October 6, 2026 notice (around October 20, 2026); monitor price recovery and six-month cure deadline in spring 2027

  • Distress Sector Watch
    👁

    Scan for further Nasdaq and NYSE deficiency notices from the same filing cohort, and for any transition from listing deficiency to Chapter 11 or going-concern language

Filing Analyses (5)
Streamex Corp. 8-K negative materiality 6/10

09-10-2026

Streamex Corp. (NASDAQ: STEX) received a Nasdaq Listing Qualifications notice on October 7, 2026, stating it is not in compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), based on 30 consecutive business days of closing bid prices from August 25, 2026 through October 6, 2026. The Company has a 180-calendar-day compliance period until April 5, 2027 to regain compliance, and the notice has no immediate effect on the listing or trading of its common stock.

  • · Nasdaq Listing Rule 5810(c)(3)(A) governs the 180-day compliance period, with a deadline of April 5, 2027
  • · If not compliant by April 5, 2027, the Company may qualify for a second 180-day period only if it meets the publicly held shares market value requirement and other initial listing standards (excluding bid price) and gives written notice of intent to cure, potentially including a reverse split
  • · A reverse stock split, if used, must be completed no later than ten business days before April 5, 2027
  • · Failure to cure may lead to a delisting notice, which can be appealed to a Nasdaq Hearings Panel
  • · The filing includes forward-looking statements citing market conditions and macroeconomic factors affecting digital asset markets, suggesting the Company's business is tied to digital assets
OWENS & MINOR INC/VA/ 8-K negative materiality 5/10

09-10-2026

Accendra Health, Inc. (NYSE: ACH), the entity formerly known as Owens & Minor Inc. (OMI) as indicated by the EDGAR header, received a notice from the NYSE on October 6, 2026 for non-compliance with Section 802.01C because its average closing price fell below $1.00 per share over 30 consecutive trading days. The notice has no immediate impact on the listing, and the company has six months to regain compliance, which it intends to pursue. The company will notify the NYSE of its intent to cure within 10 business days.

  • · Notice was received October 6, 2026 under NYSE Listed Company Manual Section 802.01C.
  • · A press release was issued October 9, 2026 and furnished as Exhibit 99.1 under Item 7.01 (not deemed filed).
  • · The notice states it does not affect business operations or SEC reporting obligations.
  • · Cure requires a closing price of at least $1.00 on the last trading day of a month, with a 30-day average also at least $1.00.
Better Home & Finance Holding Co 8-K negative materiality 7/10

09-10-2026

Better Home & Finance Holding Company notified Nasdaq on October 5, 2026 that, following board resignations and removals disclosed in 8-Ks filed October 2 and October 6, 2026, it no longer complies with several Nasdaq corporate governance rules, including board independence, audit committee, compensation committee, and independent director nomination requirements. Nasdaq's October 8, 2026 notice gives the company 45 calendar days to submit a compliance plan, and the notice has no immediate effect on the listing of its Class A common stock or warrants, though failure to regain compliance could lead to delisting.

  • · Nasdaq cited non-compliance with Listing Rule 5605(b)(1) (majority independent board), 5605(c)(2) (audit committee), 5605(d) (compensation committee), and 5605(e)(1) (independent director nominations)
  • · The company is an emerging growth company
  • · The company states it intends to submit a compliance plan within the 45-day period but gives no assurance Nasdaq will accept it
Alaunos Therapeutics, Inc. 8-K negative materiality 8/10

09-10-2026

Alaunos Therapeutics (Nasdaq: TCRT) received a written notice from Nasdaq's Listing Qualifications Staff on October 5, 2026 that its securities are subject to delisting for failing to maintain the minimum $2.5M stockholders' equity required under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market. The company, which received the initial deficiency notice on April 9, 2026 and submitted a compliance plan, intends to request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting action until the hearing and any Panel-granted extension expire. The company is also exploring strategic alternatives with a financial advisor, but management states there is no assurance the Panel will grant continued listing or that any transaction will be identified, completed, or restore compliance.

  • · Initial Nasdaq deficiency notice received April 9, 2026; company timely submitted a compliance plan
  • · Delisting notice received October 5, 2026; company plans to timely request a Nasdaq Hearings Panel hearing, which stays further suspension or delisting action
  • · Company is working with a financial advisor on one or more potential transactions it believes would restore compliance with all Nasdaq continued listing criteria
  • · Any potential transaction remains subject to negotiations, due diligence, definitive agreements, required approvals, and closing conditions
IT TECH PACKAGING, INC. 8-K negative materiality 8/10

09-10-2026

IT Tech Packaging, Inc. (NYSE American: ITP) disclosed it is not in compliance with NYSE American continued listing standards because it failed to timely file its Form 10-K for FY2025 and Forms 10-Q for the quarters ended March 31, 2026 and June 30, 2026. On October 7, 2026, NYSE Regulation accepted the company's October 1, 2026 extension request and granted a plan period through April 15, 2027 to complete the delayed filings; the stock continues to trade on NYSE American during the plan period but carries a late filer (.LF) indicator. The company says it expects to file on or before the deadline but offers no assurance it will do so.

  • · Delisting proceedings will be initiated if the company does not make progress consistent with the plan or does not complete all delayed filings by April 15, 2027; the company may appeal a staff delisting determination under Section 1010 and Part 12 of the Company Guide.
  • · The extension request was submitted October 1, 2026 and accepted October 7, 2026, and the company issued a press release on October 9, 2026 as required by Sections 402 and 1009(e) of the Company Guide.
  • · Filing references Sections 134 and 1101 of the NYSE American Company Guide as the basis for non-compliance.

Get daily alerts with 7 investment signals, 7 risk alerts, 6 opportunities and full AI analysis of all 5 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US Corporate Distress Financial Stress SEC Filings

🇺🇸 More from United States

View all →